Topic:

Partnering

Latest Headlines

Latest Headlines

Xerox invests in HealthSpot, a telemedicine provider

Xerox, best known for its copy machines and document management systems, is investing in HealthSpot, a telemedicine provider that sets up kiosks that connect patients with physicians.

Takeda's Millennium re-ups with Presage on cancer drug combo effort

Whatever Cambridge, MA-based Millennium learned over the past two years it's been collaborating with Presage Biosciences, the experience must have been rewarding.

Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device

Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.

GE Healthcare lends imaging tech to Takeda for Dx partnership

As chronic liver disease numbers continue to skyrocket, diagnostics heavyweight GE Healthcare and Japanese-based Takeda are teaming up to develop new drugs to counter the trend.

Takeda recruits GE to help discover new liver treatments

The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, has recruited the diagnostics experts at GE Healthcare to shepherd its early R&D efforts.

Foundering Aveo strikes a small deal to resurrect its thrice-failed drug

With former collaborator Astellas Pharma long since out the door, Aveo Oncology has found another partner willing to take a shot on the troubled tivozanib, signing a modest deal with Ophthotech to see how the cancer drug fares in eye diseases.

Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.

FDA taps Icon to help patients better weigh in on trials

Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.

UPDATED: Merck partners with Bind on a pair of new cancer drug programs

Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which has been investing heavily in its cancer drug pipeline, is turning over a pair of early-stage drug candidates to see if Bind's delivery technology can amp up their efficacy.

Astellas sinks deeper roots into Cambridge's hot R&D field with $1.2B pact

Just weeks ago Astellas teamed up with Harvard's Constance Cepko on a new program for a degenerative eye disease. Today it inked a deal with Proteostasis Therapeutics that could be worth up to $1.2 billion while getting Dana-Farber investigators to help hunt down new cancer drugs that can inhibit K-Ras.